Tsubota Lab has signed an exclusive implementation license agreement with shenyang xingqi pharmaceutical.
On the 5th, Tobita Lab <4890> announced that they have signed a patent license agreement with China's ophthalmology drug manufacturer Shenyang Xingqi Pharmaceutical (hereinafter referred to as Xingqi) to grant exclusive rights to certain patents in specific regions.
A Look At The Fair Value Of Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573)
Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject of the phase I clinical trial of SQ-22031 eye drops has been enrolled.
Gelonghui September 4th | Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company's research and development of SQ-22031 eye drops recently completed the first subject enrolled in the "evaluation of the safety, tolerability and pharmacokinetics of SQ-22031 eye drops in healthy subjects for single/multiple doses in a Phase I clinical trial with a single center, randomized, double-blind, placebo-controlled design", officially entering the clinical trial. The Phase I study of SQ-22031 eye drops is a randomized, double-blind, placebo-controlled single/multiple dose trial to evaluate the safety of SQ-22031 eye drops in healthy subjects and analyze the evaluation.
Sinqi Pharmaceutical: Semi-Annual Report 2024
Sinqi Pharmaceutical: 2024 Semi-Annual Report Summary
Shenyang Xingqi Pharmaceutical (300573.SZ): Net income in the first half of the year increased by 92.95% to 0.169 billion yuan and plans to distribute 5 yuan per 10 shares.
Grain Alliance reported its interim report for the first half of 2024 on August 28. During the reporting period, revenue was 0.892 billion yuan, a year-on-year increase of 30.10%; net income attributable to the shareholders of the listed company was 0.169 billion yuan, a year-on-year increase of 92.95%; net income attributable to the shareholders of the listed company excluding non-recurring gains and losses was 0.169 billion yuan, a year-on-year increase of 96.55%; basic earnings per share were 0.97 yuan; proposing a cash dividend of 5 yuan (including tax) per 10 shares to all shareholders.
Shenyang Xingqi PharmaceuticalLtd's (SZSE:300573) Three-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Shenyang Xingqi Pharmaceutical (300573.SZ): All production lines of the company have passed GMP certification.
Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interaction platform on August 16 that all production lines of the company have passed the GMP certification, and the company will arrange production according to the production and operation plan.
Shenyang Xingqi Pharmaceutical (300573.SZ): Low concentration atropine eye drops have reached cooperation with many domestic private chain medical institutions, including Aier Eye Hospital Group.
Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interactive platform on August 16th that the company's low-concentration atropine eye drops have reached cooperation with multiple private chain medical institutions in China, including Aier Eye Hospital Group.
Shenyang Xingqi Pharmaceutical (300573.SZ): Currently, the company has no new coronavirus prevention and treatment drugs.
Shenyang Xingqi Pharmaceutical (300573.SZ) stated on the investor interaction platform on August 12th that the company currently has no COVID-19 prevention and treatment drugs.
Shenyang Xingqi Pharmaceutical (300573.SZ): In 2023, the company was awarded the title of "Provincial Green Factory" and passed the evaluation and acceptance of "Zero Waste Factory".
On August 9th, Gelon Hui Corporation reported on its investor interaction platform that Shenyang Xingqi Pharmaceutical actively practices a green low-carbon strategy, introduces innovative technologies to improve its green operation level, and reduces the impact of its business operations on the environment. In 2023, the company won the title of "Provincial Green Factory" and passed the "Zero Waste Factory" appraisal and acceptance. The company fully implements the relevant regulations of the green factory, focuses on building a green supply chain, realizes the full chain digital transformation from R&D to packaging, and continuously accelerates the pace of green and low-carbon transformation, jointly promoting the industry's green and high-quality development. In the future, the company will continue to practice the ESG development concept and promote
With A 25% Price Drop For Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) You'll Still Get What You Pay For
Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%
Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-22031 eye drops obtained the notice of clinical trial approval.
On July 25th, Gelonghui reported that Shenyang Xingqi Pharmaceutical (300573.SZ) has recently received a drug clinical trial approval notice for SQ-22031 eye drops issued by the National Medical Products Administration. SQ-22031 eye drops are category 1 biological products developed by our company for treatment. In clinical trials, it is intended to be used for (1) dry eye syndrome; (2) neurotrophic keratitis. Among them, indication (2) neurotrophic keratitis was included in the second batch of rare disease catalog in China in 2023. According to the relevant requirements for category 1 biological products for therapeutic use in the registration classification of biological products, the company has completed SQ-2.
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%
Shenyang Xingqi Pharmaceutical (300573.SZ) has obtained a pharmaceutical registration certificate for Bromfenac Sodium Eye Drops.
On July 24th, Gelunhui reported that Shenyang Xingqi Pharmaceutical (300573.SZ) announced that it has recently received the "Drug Registration Certificate" for Sodium Bromfenac Eye Drops issued by the National Drug Administration. The product is an eye drop whose main component is Sodium Bromfenac. The Sodium Bromfenac Eye Drops approved by the company are multi-dose products, clinically indicated for symptomatic treatment of inflammatory diseases in the external and anterior segments of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Zhu Shaoxing disclosed the Q2 report of his fund, with a significant shareholding reduction in Kweichow Moutai (600519.SH).
Recently, Zhu Shaoxing, the star fund manager of Fund Manager, revealed the second quarter report of his fund holdings in 2024. Currently, Zhu Shaoxing only manages one fund, the Fuguo Tianhuicheng Growth Hybrid Fund, with a management scale of nearly RMB 27 billion as of the end of the second quarter.
The latest development of Zhu Shaoxing's shareholding has been exposed! He reduced his shareholding in Maotai for two consecutive quarters and increased his holdings in these companies continuously.
Continuously increasing or decreasing shareholdings of these stocks for five consecutive quarters.
Here's Why We Think Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Well Worth Watching
No Data
No Data